Speaker
Description
INTRODUCTION: Low-dose CT screening (LDCT) reduces lung cancer mortality by detecting tumours at earlier, more treatable stages, but implementing it is costly. Before France's pilot programme, IMPULSION, is extended nationwide, its efficiency needs to be established. We conducted a systematic review of European cost-effectiveness models of lung cancer screening, with methodological assessments, to identify elements relevant to a future French model.
METHODS: We searched PubMed, Embase and Cochrane (2015–2026) for European decision-analytic models evaluating the cost-effectiveness of LDCT screening. Study selection, quality assessment and data extraction, including incremental cost-effectiveness ratio (ICER) in euros per quality-adjusted life years (QALY), were performed independently by two reviewers.
RESULTS: Twenty-one studies from 14 European countries were included. ICER varied between 2,345-50,000€/QALY gained, median 11,487€, but studies rarely accounted for the same costs. Scan, diagnosis and treatment costs were included everytime, but only 66% of studies included recruitment costs (invitations, phone calls) and 24% included organisational costs (communication, infrastructure), despite their influence on real-world feasibility. Participation rates also varied widely across models (25–100%) but were rarely tested in sensitivity analyses. Costs of innovative treatment (immunotherapies/targeted therapies) were included in only 67% of studies whereas most are less than 10 years old.
CONCLUSION: These findings confirm that LDCT screening is generally cost-effective with ICERs < 50,000€/QALY, a threshold commonly considered acceptable, in populations comparable to IMPULSION's. They also highlight two under-explored determinants for a future French model: organisational costs and real-world participation, both critical to assessing the feasibility of nationwide screening in France.